Effectiveness of Focused Nursing Intervention in terms of Health Literacy, Treatment Adherence and Symptom Reduction among patients diagnosed with Gastroesophageal Reflux Disease

Start Date01 Aug 2025

Sponsor / Collaborator

Institute of Liver & Biliary Sciences

CTRI/2024/06/068480

/ Not yet recruitingNot ApplicableIIT

Right ventricle-pulmonary artery uncoupling in critically ill decompensated chronic liver disease patients: an exploratory observational study - NIL

Start Date02 Jun 2025

Sponsor / Collaborator

Institute of Liver & Biliary Sciences

NCT06909175

/ Not yet recruitingNot ApplicableIIT

Comparing Transesophageal Echocardiography and Trans Abdominal Doppler for Portal Vein Assessment in Living Donor Liver Transplantation

Liver transplantation is usually associated with hemodynamic instability. TEE allows for a real time monitoring of cardiac structures and has become a standard of care for liver transplant patients. Society of cardiovascular anaesthesia and American society of anaesthesiologists recommends use of TEE in non-cardiac surgery patients with hemodynamic instability. Also, society for advancement of transplant anaesthesia (SATA) has suggested that TEE usage in cases of liver transplant is safe, effective and improves outcomes. TEE can also provide vital information relating to non-cardiac structures including liver, spleen, kidneys, portal vein, hepatic vein and other major vessels. As of now standard protocol is to do the transabdominal doppler for the assessment of portal vein after the liver graft implantation. Hence, the aim of our study is to compare the transesophageal echocardiography and transabdominal Doppler for assessing portal vein in living donor liver transplantation.

Start Date01 Apr 2025

Sponsor / Collaborator

Institute of Liver & Biliary Sciences

100 Clinical Results associated with Institute of Liver & Biliary Sciences

0 Patents (Medical) associated with Institute of Liver & Biliary Sciences

1,563

Literatures (Medical) associated with Institute of Liver & Biliary Sciences

01 Sep 2025·Journal of Clinical and Experimental Hepatology

Predictive Factors and Nomogram (MAP-BNP) for Post Stereotactic Body Radiotherapy Survival in Advanced Hepatocellular Carcinoma Patients

Author: Kumar, Guresh ; Sharma, Deepti ; Sarin, Shiv Kumar ; Yadav, Hanuman Prasad ; Jagya, Deepak ; Meena, Babu Lal ; V, Anju K.

Stereotactic body radiation therapy (SBRT) is a widely recognized approach for managing hepatocellular carcinoma (HCC), particularly in its advanced stages, with prognosis highly dependent on tumor burden and baseline liver function.This study aimed to develop a predictive model and nomogram that incorporates these factors to improve survival outcomes in advanced HCC patients treated with SBRT and systemic therapy.We retrospectively reviewed records of 110 patients with advanced HCC treated with SBRT between May 2020 and Apr. 2023.Inclusion criteria included age ≥18 years, cirrhosis, and suitability for SBRT.The median age was 63 years (range 28-84), with viral cirrhosis (40.9%) and NASH (38.2%) as the main etiologies.At presentation, 83.6% of patients had portal vein thrombosis, 32.7% had nodal metastasis, and 50% had distant metastasis.The median tumor diameter was 9 cm, and 73.6% of patients had the multifocal disease.A median SBRT dose of 35 Gy (range 25-45 Gy) in 5 fractions was administered.Significant reductions in tumor markers were noted at three months: AFP levels dropped from a median of 309.75 ng/mL to 62 ng/mL (P = 0.015), and PIVKA II from 2230 mAU/mL to 345 mAU/mL (P = 0.001).Complete and partial responses were seen in 33% and 45% of patients, resp.The median overall survival (OS) was 14 mo (95% CI 11.7-16.2), with OS rates of 90%, 58%, and 34% at 6, 12, and 24 mo.Progression-free survival (PFS) was 9 mo (95% CI 6.4-11.5).Significant predictors of OS included multifocal tumor, portal vein thrombosis, lymph node involvement, serum bilirubin, serum albumin, and log PIVKA-II.The developed MAP-BNP nomogram achieved a C-index of 0.853, outperforming the Child-Turcotte-Pugh (0.62) and ALBI (0.64) scores.Patients were classified into low-risk (<200 points) and high-risk (>200 points) groups, with the low-risk group showing a significantly longer OS (P < 0.001).The MAP-BNP nomogram, integrating tumor burden and liver function, provides a more individualized approach for predicting survival in advanced HCC patients treated with SBRT and systemic therapy, outperforming traditional staging systems.

01 Jul 2025·Biosensors and Bioelectronics

Single-shot, receptor-free, rapid detection and classification of five respiratory viruses by machine learning integrated SERS sensing platform

Article

Author: Yadav, Arti ; Srivastava, Sachin K ; Roy, Partha Pratim ; Naik, Rakesh ; Gupta, Ekta

A machine learning integrated SERS sensing platform is developed for a single-shot, receptor-free, rapid detection and classification of five respiratory viruses including Influenza A, Respiratory Syncytial Virus (RSV), Human Rhinoviruses (Rhino), and two variants of SARS-CoV-2 virus such as Omicron and Delta in clinical nasal and/or nasopharyngeal samples (CNS) in viral transport media (VTM). SERS sensor composed of Ag nano-sculptured thin film (nSTF) is fabricated by glancing angle deposition (GLAD) technique and possess a SERS enhancement factor of the order of 10¹¹. Various machine learning (ML) algorithms like Random Forest Classifier (RF), Support Vector Machine (SVM), Logistic Regression (LR), k-Nearest Neighbor (KNN), and Multilayer Perceptron (MLP) are trained on SERS spectra dataset of CNS for classification of the viruses. MLP shows the best performance for the analysis and classification of complex SERS spectra with a 5-fold validation accuracy of 97.61 ± 0.30 %, test accuracy 97.47 %, sensitivity 97 %, precision 97 %, and specificity 99 %. The SERS sensor integrated with ML has a rapid response of 11 minutes, which makes it appropriate for practical implementations in clinical environments, speeding up virus detection and efficient management of respiratory viral infections.

01 Jul 2025·Journal of Clinical and Experimental Hepatology

Predictors of Non-response to Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma: A Multicentre Real World Study (HCC-AB Study)

Article

Author: Duseja, Ajay ; Kumar, Karan ; Shah, Samir ; Rathi, Sahaj ; Nagaraja Rao, P ; Kumar, Guresh ; Taneja, Sunil ; Singh, Satender P ; Sarin, Shiv K ; Saraswat, Vivek ; Choudhury, Ashok ; Arora, Vinod ; Chaubal, Alisha ; Kumar, Ashish ; Kulkarni, Anand

BackgroundThe approved immunotherapies for patients with advanced HCC are Atezolizumab and Bevacizumab. However, patients in India present late and healthcare is often available through self-financing. To rationalise the therapy, we conducted a large multicentre study to identify the baseline predictors of non-response to atezolizumab and bevacizumab in advanced unresectable HCC.MethodsA dose of atezolizumab 1200 mg and bevacizumab 15 mg/kg was used every 3 weeks from 6 centres across India. A total of 278 patients were screened, and 160 were included in the study. The study included patients with locally advanced metastatic or inoperable hepatocellular carcinoma who were at least 18 years of age and those who received <3 injections were excluded. Fifty-four percent of the included patients were BCLC-B and 46% were BCLC-C. The primary objective was to study overall survival and progression-free survival. While identifying radiological response, objective response rate and adverse effects were secondary objectives.ResultsThe mean age was 61.9 ± 11.7 years, 88% were male, 55% had NASH, 16.3% had hepatitis C, 18.8% had hepatitis B and the rest were alcohol. The mean Model for End-Stage Liver Disease (MELD) is 12.05 ± 4.46, Albumin-Bilirubin Score (ALBI) is -2.04 ± 0.57. Fifty-five percent received first-line and 45% as second/other line therapy. The median overall survival was 10 (95% confidence interval [CI]: 6.1-15.6) months. Progression-free survival was found to be 8 (95%CI: 5.1-14.7) months overall. Eleven (6.9%) achieved complete response, 28 (17.5%) partial response, 33 (20.6%) had stable disease and 88 (55%) had progressive disease. On multivariate analysis, CRP>1 mg/dl (P-0.007), PIVKA-II>400 mAU/mL (P-0.019), AFP>100 ng/ml (P-0.009), presence of diabetes (P-0.042) were associated with non-response to atezolizumab and bevacizumab injection. Fifty-three percent of patients developed any grade of adverse effect, and 20% developed grade 3/4 adverse events amounting to the stoppage of therapy.ConclusionNon-response to atezolizumab and bevacizumab immunotherapy was predicted by CRP>1 mg/dl, PIVKA-II>400mAU/ml, AFP>100 ng/ml and the presence of diabetes.

100 Deals associated with Institute of Liver & Biliary Sciences

100 Translational Medicine associated with Institute of Liver & Biliary Sciences

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 31 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Thiourea derivatives DSA-09(Institute of Liver and Biliary Sciences) ( HBX )	Hepatitis B More	Preclinical
Thiourea derivatives DSA-00(Institute of Liver and Biliary Sciences) ( HBX )	Hepatitis B More	Preclinical
Thiourea derivatives DSA-02(Institute of Liver and Biliary Sciences) ( HBX )	Hepatitis B More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis